HaCaT cells as a model system to study primary cilia in keratinocytes.
cancer
differentiation
keratinocyte biology
keratinocytes
primary cilium
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
09
05
2022
received:
03
01
2022
accepted:
13
06
2022
pubmed:
17
6
2022
medline:
19
8
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
Primary cilium (PC) is a microtubule-based organelle found on the apical surface of most mammalian cell types, playing a role in development and tissue homeostasis. Ciliopathies are a rapidly growing group of human diseases characterized by disordered cilium. PC plays an important role in pathogenesis of basal cell cancer, the most common human malignancy. A significant increase in ciliation has been observed in the epidermis of atopic dermatitis and psoriasis patients. Spontaneously immortalized human keratinocytes, HaCaT are a model to study the epidermal homeostasis and pathophysiology. In contrast to what has been previously described, here, we show that HaCaT can be efficiently ciliated. In HaCaT cells, differentiation significantly increased the number of ciliated cells and we were able to analyse in detail the ciliary length progression with duration of differentiation. As the number of recognized ciliopathies continues to increase, the importance of ciliary models also rises. Even though keratinocytes do not become as highly and rapidly ciliated as cell lines frequently used in ciliary studies, they are a better model for the study of skin ciliopathies. Detailed progression of ciliation in HaCaT could serve as the basis for ciliary studies in this cell line.
Identifiants
pubmed: 35708968
doi: 10.1111/exd.14626
pmc: PMC9542831
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1276-1280Informations de copyright
© 2022 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
Références
Science. 2006 Aug 4;313(5787):629-33
pubmed: 16888132
J Cell Sci. 2018 Jan 8;131(1):
pubmed: 29180513
Cilia. 2016 Aug 04;5:23
pubmed: 27493724
J Biol Chem. 2015 Jul 10;290(28):17163-72
pubmed: 25957412
Cell Mol Life Sci. 2017 Nov;74(22):4077-4095
pubmed: 28624967
Mol Carcinog. 1998 Nov;23(3):144-58
pubmed: 9833775
Trends Cell Biol. 2017 Feb;27(2):126-140
pubmed: 27634431
Nat Rev Genet. 2010 May;11(5):331-44
pubmed: 20395968
Exp Dermatol. 2021 Jun;30(6):792-803
pubmed: 33455013
Clin Cancer Res. 2012 May 1;18(9):2429-35
pubmed: 22415315
Mediators Inflamm. 2017;2017:7435621
pubmed: 29391667
Cell Cycle. 2007 Sep 1;6(17):2152-60
pubmed: 17786050
Methods Mol Biol. 2014;1195:33-41
pubmed: 24155234
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
J Invest Dermatol. 2019 Jul;139(7):1439-1448
pubmed: 30707899
Development. 2011 May;138(9):1675-85
pubmed: 21429982
Exp Dermatol. 2022 Aug;31(8):1276-1280
pubmed: 35708968
Biochem J. 2018 Jul 31;475(14):2329-2353
pubmed: 30064990
Nat Rev Nephrol. 2019 Apr;15(4):199-219
pubmed: 30733609
PLoS Genet. 2019 Jan 28;15(1):e1007914
pubmed: 30689641
Exp Cell Res. 2017 Dec 15;361(2):333-341
pubmed: 29097185
Front Cell Dev Biol. 2020 Nov 13;8:578384
pubmed: 33282860
Commun Biol. 2021 May 10;4(1):544
pubmed: 33972689
Front Cell Dev Biol. 2021 Jan 07;8:622918
pubmed: 33585461
Nat Rev Mol Cell Biol. 2017 Sep;18(9):533-547
pubmed: 28698599